ID   A549/DDP
AC   CVCL_C0W4
DR   cancercelllines; CVCL_C0W4
DR   CLS; 305047
DR   Wikidata; Q114310532
RX   PubMed=28114404;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: UniProtKB; P42212; GFP.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=28114404; DOI=10.1371/journal.pone.0170609;
RA   Fang Y.-N., Zhang C., Wu T., Wang Q., Liu J.-H., Dai P.-G.;
RT   "Transcriptome sequencing reveals key pathways and genes associated
RT   with cisplatin resistance in lung adenocarcinoma A549 cells.";
RL   PLoS ONE 12:E0170609-E0170609(2017).
//